AI Analysis AI Analysis of RARE
Powered by GPT-4o
New!
Stock Analysis PRO
Stock Analysis
Risk Assessment
Trading Strategy
PDF

Ultragenyx Pharmaceutical Inc. stock downgraded from Hold/Accumulate to Sell Candidate after Friday trading session
(Updated on Jun 20, 2025)

Sell candidate since Jun 20, 2025

The Ultragenyx Pharmaceutical Inc. stock price fell by -0.562% on the last day (Friday, 20th Jun 2025) from $37.35 to $37.14. During the last trading day the stock fluctuated 2.81% from a day low at $36.45 to a day high of $37.48. The price has fallen in 5 of the last 10 days but is still up by 0.62% over the past 2 weeks. Volume has increased on the last day by 134 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $40.31 million.

The stock is moving within a very wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect Ultragenyx Pharmaceutical Inc. stock with a 90% probability to be traded between $32.23 and $40.42 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stock seldom manage to go directly from the bottom of a trend up to the top. Stock turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Investment opportunities can be found at any hour. So, react immediately to market-moving news and capture more market opportunities when convenient for you. You can trade over 10,000 US Stocks and ETFs, US Equity Index options, US Treasuries – and more - around the clock . Interactive Brokers’ dual market centers ensure reliable and dependable overnight trading on your timetable. (Member SIPC)
IBKR Logo

RARE Signals & Forecast

The Ultragenyx Pharmaceutical Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $37.51. On a fall, the stock will find some support from the long-term average at approximately $36.35. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, June 12, 2025, and so far it has fallen -5.47%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Sell
Special Signal Notification

Double Top Formation

Double Top Formation A sell signal from a double top formation was found on Thursday, June 12, 2025 and based on theory for this formation the price should fall by -0.96% to $36.78 within 28 trading days (Thursday, July 24, 2025) since signal was issued.

Support, Risk & Stop-loss for Ultragenyx Pharmaceutical Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $34.35 and $33.91. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Ultragenyx Pharmaceutical Inc. finds support just below today's level at $34.35. If this is broken, then the next support from accumulated volume will be at $33.91 and $33.16.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.03 between high and low, or 2.81%. For the last week, the stock has had daily average volatility of 3.52%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (RARE) For The Upcoming Trading Day Of Monday 23rd

For the upcoming trading day on Monday, 23rd we expect Ultragenyx Pharmaceutical Inc. to open at $37.02, and during the day (based on 14 day Average True Range), to move between $35.69 and $38.59, which gives a possible trading interval of +/-$1.45 (+/-3.92%) up or down from last closing price. If Ultragenyx Pharmaceutical Inc. takes out the full calculated possible swing range there will be an estimated 7.83% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $37.35 (0.57%) than the support at $34.35 (7.51%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Ultragenyx Pharmaceutical Inc. stock A Buy?

Ultragenyx Pharmaceutical Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Current score: -1.220 Sell Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on June 23, 2025 - $37.02 ( 0.319%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*

RARE Performance

Trading levels for RARE

Full Access. No Commitment. 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis Powered by GPT-4o*
Top 5 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 38.05 2.44%
R2 37.66 1.39%
R1 37.41 0.736%
Price 37.14
S1 36.63 -1.37%
S2 36.39 -2.02%
S3 36.00 -3.08%

Accumulated Volume Support & Resistance Levels

Level Price
R3 39.29 5.79%
R2 37.51 1.00%
R1 37.35 0.565%
Price 37.14
S1 34.35 -7.51%
S2 33.91 -8.70%
S3 33.16 -10.72%

FAQ

What is the symbol for Ultragenyx Pharmaceutical Inc. Stock and on which exchange is it traded?
The symbol for Ultragenyx Pharmaceutical Inc. is RARE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Ultragenyx Pharmaceutical Inc. Stock?
Ultragenyx Pharmaceutical Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

How to buy Ultragenyx Pharmaceutical Inc. Stock?
Ultragenyx Pharmaceutical Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Ultragenyx Pharmaceutical Inc. Stock.

What's the current price of Ultragenyx Pharmaceutical Inc. Stock?
As of the end of day on the Jun 20, 2025, the price of an Ultragenyx Pharmaceutical Inc. (RARE) share was $37.14.

What is the 52-week high and low for Ultragenyx Pharmaceutical Inc. Stock?
The 52-week high for Ultragenyx Pharmaceutical Inc. Stock is $60.37 and the 52-week low is $29.59.

What is the market capitalization of Ultragenyx Pharmaceutical Inc. Stock?
As of the Jun 20, 2025, the market capitalization of Ultragenyx Pharmaceutical Inc. is 3.511B.

When is the next earnings date for Ultragenyx Pharmaceutical Inc.?
The upcoming earnings date for Ultragenyx Pharmaceutical Inc. is Aug 07, 2025.
Click to get the best stock tips daily for free!
ABOUT ULTRAGENYX PHARMACEUTICAL INC.
Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...
GOLDEN STAR
Ticker Change Signal Date
G
GTM
$9.57
2.40% Jun 02
TAC
$8.90
23.37% May 12
IMMR
$7.28
4.81% May 09
UAA
$5.84
20.38% May 09
MEDP
$300.81
2.84% May 08

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE